Non-small Cell Lung Cancer (Part E)
1 clinical trials · Condition
◉ Watch Non-small Cell Lung Cancer (Part E)
| Record | Firm | Date |
|---|---|---|
| A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 (NCT02637531) | Infinity Pharmaceuticals, Inc. | 2015-12-01 |
Track Non-small Cell Lung Cancer (Part E) automatically
Every clearance here is in the API, with alerts when new ones post.